How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundaci-n-centro-nacional-de-investigaciones-cardiovasculares-carlos-iii.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
FDC	FDC	phase 3			Cardiovascular
Cardiovascular Polypill	Cardiovascular Polypill	phase 3	Fixed-dose combination / Polypill		Cardiovascular
Treatment Prevention for Secondary CV	Treatment Prevention for Secondary CV	phase 3	PCSK9 inhibitor	PCSK9	Cardiovascular

Therapeutic area mix

Cardiovascular · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Allergan · 1 shared drug class
Amgen · 1 shared drug class
Amgen Research (Munich) GmbH · 1 shared drug class
Bayer · 1 shared drug class
Beijing Anzhen Hospital · 1 shared drug class
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 shared drug class
Hospital General Universitario Gregorio Marañon · 1 shared drug class
Novartis · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III:

Cite this brief

Drug Landscape (2026). Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-centro-nacional-de-investigaciones-cardiovasculares-carlos-iii. Accessed 2026-05-17.